Phathom Pharmaceuticals Inc. Insider Trading

PHAT

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in May 2025.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

May 2025

May 21, 2025

Get an email when PHAT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 3, 2025	Robert Charles Breedlove Principal Accounting Officer	SoldNo plan	524	$13.51	7K	1.0%	Form 4
Sep 5, 2025	Robert Charles Breedlove Principal Accounting Officer	SoldNo plan	461	$12.09	6K	0.8%	Form 4
Jul 16, 2025	Robert Charles Breedlove Principal Accounting Officer	SoldNo plan	1,692	$8.36	14K	3.1%	Form 4
May 21, 2025	James N Topper Director	Bought	3,780	$3.86	15K	<0.1%	Form 4
May 13, 2025 – May 14, 2025	James N Topper Director	Bought 2 parts	7,420	$3.30 average	24K	0.1%	Form 4
May 9, 2025 – May 12, 2025	James N Topper Director	Bought 3 parts	48,203	$3.17 average	153K	0.8%	Form 4
May 6, 2025 – May 7, 2025	Asit Parikh Director	Bought 2 parts	10,000	$2.50 average	25K	12%	Form 4
Apr 7, 2025	Molly Henderson CFO and CBO	SoldNo plan	3,678	$4.55	17K	3.9%	Form 4
Mar 13, 2025	Asit Parikh Director	Bought	10,000	$4.42	44K	13%	Form 4
Jan 21, 2025	Molly Henderson CFO and CBO	SoldNo plan	6,583	$6.59	43K	6.5%	Form 4
Jan 21, 2025	Azmi Nabulsi Chief Operating Officer	SoldNo plan	7,886	$6.59	52K	0.8%	Form 4
Jan 21, 2025	Terrie Curran President and Chief Executive	SoldNo plan	19,109	$6.59	126K	5.0%	Form 4
Dec 19, 2024	Azmi Nabulsi Chief Operating Officer	SoldNo plan	1,118	$8.00	9K	0.1%	Form 4
Dec 19, 2024	Molly Henderson CFO and CBO	SoldNo plan	1,291	$8.00	10K	1.3%	Form 4
Dec 13, 2024	Frank Karbe Director	Bought	12,500	$7.93	99K	28%	Form 4
Dec 13, 2024	Asit Parikh Director	Bought	10,000	$8.12	81K	15%	Form 4

Nov 3, 2025No plan
Robert Charles Breedlove
Principal Accounting Officer · sold 524 at $13.51
7K
1.0% of stake
Sep 5, 2025No plan
Robert Charles Breedlove
Principal Accounting Officer · sold 461 at $12.09
6K
0.8% of stake
Jul 16, 2025No plan
Robert Charles Breedlove
Principal Accounting Officer · sold 1,692 at $8.36
14K
3.1% of stake
May 21, 2025
James N Topper
Director · bought 3,780 at $3.86
15K
<0.1% of stake
May 13, 2025 – May 14, 2025
James N Topper
Director · bought 7,420 at avg $3.30
24K
0.1% of stake
May 9, 2025 – May 12, 2025
James N Topper
Director · bought 48,203 at avg $3.17
153K
0.8% of stake
May 6, 2025 – May 7, 2025
Asit Parikh
Director · bought 10,000 at avg $2.50
25K
12% of stake
Apr 7, 2025No plan
Molly Henderson
CFO and CBO · sold 3,678 at $4.55
17K
3.9% of stake
Mar 13, 2025
Asit Parikh
Director · bought 10,000 at $4.42
44K
13% of stake
Jan 21, 2025No plan
Molly Henderson
CFO and CBO · sold 6,583 at $6.59
43K
6.5% of stake
Jan 21, 2025No plan
Azmi Nabulsi
Chief Operating Officer · sold 7,886 at $6.59
52K
0.8% of stake
Jan 21, 2025No plan
Terrie Curran
President and Chief Executive · sold 19,109 at $6.59
126K
5.0% of stake
Dec 19, 2024No plan
Azmi Nabulsi
Chief Operating Officer · sold 1,118 at $8.00
9K
0.1% of stake
Dec 19, 2024No plan
Molly Henderson
CFO and CBO · sold 1,291 at $8.00
10K
1.3% of stake
Dec 13, 2024
Frank Karbe
Director · bought 12,500 at $7.93
99K
28% of stake
Dec 13, 2024
Asit Parikh
Director · bought 10,000 at $8.12
81K
15% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PHAT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PHAT

CompareIntrinsic value

HROWHarrow Inc.

$28.75+0.74%46

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

SDGRSchrodinger, Inc.

$28.52+4.93%36

SNDXSyndax Pharmaceuticals Inc.

$10.45-26.87%0

RYTMRhythm Pharmaceuticals Inc.

$110.68+28.04%40

AUPHAurinia Pharmaceuticals Inc.

$17.11+3.32%58

Held by ETFs

PHAT is in 20 US ETFs. The largest of them, with PHAT's weight in each:

Spot a number that looks wrong? Check it in PHAT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PHAT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.